As of November 6, 2026, BIO-TECHNE Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 26, 2026 (Form 8-K, June 26, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like BIO-TECHNE Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BIO-TECHNE Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-26. Every row below is cited to the filing it comes from, and this page adds each new change as BIO-TECHNE Corp files it.
Also on the record for BIO-TECHNE Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 0.7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 8.1% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 5% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.38% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 2.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 5.6% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs BIO-TECHNE Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on BIO-TECHNE Corp and the records around it.
BIO-TECHNE Corp elsewhere on the record
Companies that share a holder
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch BIO-TECHNE Corp
Get an email when BIO-TECHNE Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BIO-TECHNE Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BIO-TECHNE Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BIO-TECHNE Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-26 | Reported | not named in the filing | 8-K, 2026-06-26 |
New leaders reset buying decisions — get the Full Report on BIO-TECHNE Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at BIO-TECHNE Corp, with the record behind each one.
Find candidates like senior executive at BIO-TECHNE CorpEvery change, in the filing's words
Reported
Notwithstanding the foregoing, the named executive officers will not be entitled to receive this gross-up benefit if the Merger Agreement is terminated in accordance with its terms.
- On June 23, 2026, in connection with the contemplated Merger, the Compensation Committee of the Board (the "Compensation Committee") approved cash retention bonus awards to each of the Company's current named executive officers pursuant to retention agreements (the "Retention Agreements") in order to encourage the Company's named executive officers to remain with the Company and motivate their continued strong performance until the Effective Time.
- The Retention Agreements became effective only upon the execution of the Merger Agreement.
- The Compensation Committee approved the following lump sum cash bonus amounts (the "Retention Bonuses") payable to the Company's named executive officers under the Retention Agreements: Kim Kelderman - $2,120,976; Jim Hippel - $1,541,510; William Geist - $1,161,014; Shane Bohnen - $971,097; and Steve Crouse - $910,263.
- Payment of the Retention Bonus is also subject to the officer's timely execution of a release of claims in a form provided by the Company.
Tools for this story
Each opens in a new tab, filled in for BIO-TECHNE Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.